Thioguanine /6-TG / Tioguanina
Product Overview
| Generic Name | Thioguanine /6-TG / Tioguanina |
| Brand Name(s) | Tabloid®, Lanvis® |
| Category | Antineoplastic / Cancer |
| Form | Oral tablet |
| Strength | 40mg |
| Therapeutic Class | Purine analogue antimetabolite; cytotoxic antineoplastic. |
| ATC Code | L01BB03 |
Manufacturing & Regulatory
| Manufacturer | GSK, Taj |
| GMP Compliance | WHO-GMP |
| COFEPRIS | N/A, not in cuadro basico |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW, HS 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | Request cytotoxic chemotherapy SDS |
| CTD Summary (PDF) | Proprietary; available only under NDA/CDA and serious commercial/regulatory commitment |
Special Notes
Thioguanine is a cytotoxic purine analogue used mainly for remission induction and consolidation in acute non-lymphocytic leukemia/AML. It is not generally recommended for long-term maintenance because of hepatic toxicity risk and should be used only under hematology/oncology supervision.